

SEP. 16. 2003. 3:45PM

AVENTIS US PAT DEPT

NO. 2153 P. 2

#6  
9/23/03  
C. Stafe

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
James Hendrix et al

Examiner: Patel, Sudhaker B

Art Unit: 1624

Application No.: 10/078,225

Filed: February 19, 2002

Title: NOVEL HETEROCYCLIC  
SUBSTITUTED CARBONYL  
DERIVATIVES AND THEIR USE AS  
DOPAMINE D3 RECEPTOR LIGANDS

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, on

September 16, 2003

Date of Transmission

Signature

Mail Stop Art Unit 1624  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

This paper is filed in response to the Office Action of May 16, 2003.

In response to the Restriction Requirement imposed by the Examiner in the above-referenced Office Action, Applicant hereby provisionally elects Group III. Applicant hereby provisionally elects the species described in Claim 28, which corresponds to the final product described in Example 34 of the specification.

The Commissioner is hereby authorized to charge any additional fees (or credit any overpayment) associated with this communication to our Deposit Account No. 18-1982. If a fee is required for an extension of time under 37 C.F.R. Section 1.136 not accounted for above, such extension is requested and should also be charged to our Deposit Account.

Respectfully submitted,



Barbara E. Kurys, Reg. No. 34,850  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-2965  
Telefax (908) 231-2626

Aventis Docket No. A4015 US NP

RECEIVED  
CENTRAL FAX CENTER  
SEP 17 2003

OFFICIAL

**FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE**

Applicants Docket Number:  
A 4015 US NP

Applicants:  
James Hendrix et al

Serial No.  
10/078,225

Filing Date:  
February 19, 2002

Title of Invention:  
**NOVEL HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE  
D3 RECEPTOR LIGANDS**

**CERTIFICATE OF TRANSMISSION**

I hereby certify that this correspondence is being transmitted via  
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450, Art Unit 1624, at 703-872-9306, on

Date of Deposit: September 16, 2003

Printed Name of Person Signing Certificate: Geneva Walker

Signature: *Geneva Walker*

Total Number of Pages Sent: 3

Attorney: Barbara E. Kurys

Group Art Unit: 1624

Examiner: Patel, Sudhaker B

TO: Mail Stop Art Unit 1624  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet,  
signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit  
account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- |  |  |
|--|--|
| <input type="checkbox"/> Amendment, 37 CFR _____               | <input type="checkbox"/> Fee Transmittal   |
| <input type="checkbox"/> Charge deposit account, in duplicate  | <input type="checkbox"/> Petition under 37 CFR _____   |
| <input checked="" type="checkbox"/> Extension of Time Petition | <input type="checkbox"/> Other _____   |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input checked="" type="checkbox"/> Other <u>Response to Restriction</u><br><u>Requirement</u> |
| <input type="checkbox"/> Maintenance Fee Transmittal           |  |

Receipt Confirmed:

RECEIVED  
CENTRAL FAX CENTER  
SEP 17 2003

OFFICIAL

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)  
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this  
telecopy in error, please immediately notify the sender by telephone in arrears for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)